Last Updated on December 24, 2023 by The Health Master
USFDA Approval
In a significant development, Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has achieved a major milestone by obtaining the final nod from the esteemed US Food & Drug Administration (USFDA) for the production and distribution of a generic Icatibant injection.
Icatibant injection is widely employed in the treatment of a genetic disorder known as hereditary angioedema.
The approval comes as a testament to Aurobindo Pharma’s commitment to providing effective and affordable healthcare solutions to the masses.
Let’s delve into the details of this groundbreaking achievement.
USFDA Greenlight for Eugia Pharma Specialities’ Icatibant Injection
Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma, has secured the coveted seal of approval from the USFDA for its Icatibant injection.
This injection, available in the strength of 30 mg/3 mL (10 mg/mL) as a single-dose pre-filled syringe, is a vital therapeutic option in the management of hereditary angioedema—a condition characterized by episodes of severe swelling beneath the skin, in the airways, and other body organs.
Hereditary angioedema (HAE) is an autosomal dominant disease caused by either a lack of C1-inhibitor protein or dysfunctional C1-inhibitor protein. HAE manifests with symptoms related to angioedema of the upper airway, skin, and/ or gastrointestinal tract.
Equivalent to FIRAZYR by Takeda Pharmaceuticals USA Inc
The approved Icatibant injection by Eugia Pharma Specialities stands as a bioequivalent and therapeutically equivalent alternative to the reference listed drug FIRAZYR, initially developed by Takeda Pharmaceuticals USA Inc.
This achievement underscores Aurobindo Pharma’s dedication to delivering high-quality medications that meet the same therapeutic standards as established brands, while also offering more accessible options to patients.
Upcoming Launch and Market Impact
Anticipating an official product launch in September 2023, Aurobindo Pharma is on track to introduce its Icatibant injection to the market.
This product launch is poised to have a significant positive impact on patients suffering from hereditary angioedema, providing them with a trusted and cost-effective treatment alternative.
Market Size and Potential
Based on data provided by IQVIA, Aurobindo Pharma has projected that the newly approved Icatibant injection holds a substantial estimated market size, amounting to approximately USD 137 million.
This estimation covers the period of the preceding 12 months, ending in June 2023.
Such promising market potential underscores the demand for effective hereditary angioedema treatments and highlights the strategic position of Aurobindo Pharma in addressing this need.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model, to rewrite and present the news / article in a unique format.
USFDA gives approval for this drug to treat Rare Blood Disease
USFDA gives nod for Potassium Chloride for Injection Concentrate
USFDA gives nod for Bromfenac Ophthalmic Solution, Metoprolol Tablets
USFDA gives approval for Doxycycline Hyclate delayed-release Tablets
USFDA gives approval for this Skin and Bone Infections Drug
USFDA gives nod for generic Indomethacin suppositories
National Policy ready for R&D in Pharma-Medical Device Industry
USFDA gives approval for this drug to treat Rare Blood Disease
India launches Rs 5,000 Crore R&D Incentive Scheme for Pharma Industry
Major FDA audit findings about Equipment and Instruments
DCGI issued alert for falsified this diabetes management drugs
Govt collaborates with Pharma Industry to lower prices of Rare Disease Medicines
Procedural lapses flagged at Aurobindo Pharma by USFDA: Telangana
Pharma Company Manager arrested for supplying Banned Drugs
Equipment and Instruments: Maintenance, difference and importance in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
